Simplex Trading, LLC Blueprint Medicines Corp Transaction History

Simplex Trading, LLC

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$85.18 - $108.78 $766 - $979	9 Added 0.33%	2,724 $293,000
Q1 2024 Apr 25, 2024	BUY	$73.17 - $99.79 $198,656 - $270,929	2,715 New	2,715 $257,000
Q3 2023 Nov 01, 2023	BUY	$46.9 - $66.0 $280,368 - $394,548	5,978 Added 41.16%	20,502 $1.03 Million
Q2 2023 Aug 04, 2023	BUY	$42.2 - $66.37 $600,674 - $944,710	14,234 Added 4908.28%	14,524 $917,000
Q1 2023 Apr 27, 2023	BUY	$37.97 - $50.0 $11,011 - $14,500	290 New	290 $13,000
Q2 2022 Aug 03, 2022	SELL	$45.23 - $70.15 $116,195 - $180,215	-2,569 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$54.1 - $110.08 $109,173 - $222,141	2,018 Added 366.24%	2,569 $164,000
Q2 2021 Aug 12, 2021	BUY	$82.78 - $101.0 $45,611 - $55,651	551 New	551 $48,000
Q1 2021 Apr 26, 2021	SELL	$90.71 - $108.28 $46,080 - $55,006	-508 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$92.08 - $124.48 $46,776 - $63,235	508 New	508 $0
Q2 2020 Jul 13, 2020	SELL	$57.09 - $79.27 $5,709 - $7,927	-100 Closed	0 $0
Q1 2020 Apr 29, 2020	BUY	$48.11 - $82.22 $4,811 - $8,222	100 New	100 $5,000
Q4 2019 Feb 05, 2020	SELL	$66.73 - $82.59 $146,672 - $181,532	-2,198 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$72.9 - $101.41 $160,234 - $222,899	2,198 New	2,198 $161,000
Q3 2018 Oct 23, 2018	SELL	$58.91 - $78.32 $264,152 - $351,186	-4,484 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$60.96 - $101.18 $273,344 - $453,691	4,484 New	4,484 $284,000
Q1 2018 Apr 26, 2018	SELL	$73.28 - $102.95 $94,091 - $132,187	-1,284 Closed	0 $0
Q4 2017 Jan 10, 2018	BUY	$62.91 - $88.32 $80,776 - $113,402	1,284	1,284 $96,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.